REFRACTORY MALIGNANT SOLID NEOPLASM
Clinical trials for REFRACTORY MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug shows promise for rare genetic cancers
Disease control OngoingThis study tests a drug called trametinib in 50 patients whose cancers have a specific genetic change called an NF1 mutation. The drug blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing.
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New drug targets AKT mutations in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ipatasertib in people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the drug can shrink…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Precision drug ivosidenib tested in kids with tough IDH1 cancers
Disease control OngoingThis study tests a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have either returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors. Only 3 participants were enrolled,…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Targeted drug shows promise for HER2-Mutated cancers
Disease control OngoingThis study tests a drug called afatinib in 40 patients whose advanced cancers have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or slo…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
New hope for tough cancers: drug targets genetic weakness
Disease control OngoingThis study tests a drug called afatinib in people with advanced cancers (excluding certain lung cancers) or lymphomas that have a specific change in the EGFR gene. The drug blocks signals that make cancer cells grow. The goal is to see if it can shrink or slow tumors in patients …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
Targeted drug shows promise for rare cancers with ALK mutation
Disease control OngoingThis study tested the drug crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink or stop the growth of these tumors. Only 5 patients took part, and the study is no longer enrolling new…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:50 UTC
-
Targeted drug shows promise for rare EGFR-Mutant cancers
Disease control OngoingThis study tests a drug called osimertinib in people with advanced cancers that have specific EGFR gene mutations. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or slow the disease. The trial includes 19 adults with vario…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
New drug targets rare genetic flaw in advanced cancers
Disease control OngoingThis study tests a drug called MLN0128 (TAK-228) in 35 adults with advanced cancers that have a specific genetic change (mTOR mutation). The drug works by blocking certain enzymes that cancer cells need to grow. The main goal is to see if the drug can shrink or stop the cancer fr…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Targeted drug shows promise for rare BRAF-driven cancers
Disease control OngoingThis study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF gene mutations or fusions. The goal was to see if trametinib could shrink tumors or stop them from growing by blocking certain proteins. The trial is no longer recruiting, and results…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a combination of two drugs, trametinib and navitoclax, in people with advanced solid tumors that have specific mutations in the KRAS or NRAS genes. The goal is to find the safest dose and see if the drugs can shrink tumors or slow their growth. About 96 participa…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New drug cocktail aims to starve and block cancer growth
Disease control OngoingThis early-phase trial tested a combination of two drugs (cediranib and selumetinib) in 19 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see how well the drugs worked together. Cediranib cuts off blo…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Targeted therapy shows promise for rare HER2-Positive cancers
Disease control OngoingThis study tests a drug called ado-trastuzumab emtansine in people with advanced cancers that have too many HER2 receptors (HER2 amplification), except breast and stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Rese…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New combo targets Cancer's DNA repair weakness
Disease control OngoingThis study tests a combination of two drugs (avelumab and M6620) in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see how well the drugs work together t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like atypical teratoid/rhabdoid tumors or epithelioid sarcoma) have returned or not responded to treatment. These cancers lack certain genes, making them hard to tre…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New drug combo aims to stall advanced cancers that failed prior therapy
Disease control OngoingThis phase 2 trial tests whether combining nilotinib (a targeted pill) with paclitaxel (a standard chemo) can shrink or slow advanced solid tumors that have already been treated with taxane chemo and are still growing. About 40 adults with progressive metastatic or refractory sol…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New drug targets rare gene fault in advanced cancers
Disease control OngoingThis study tests a drug called erdafitinib in people with advanced cancers that have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that haven't responded to other treatments…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:45 UTC
-
New chemo wrap targets tumors deeper, spares healthy cells
Disease control OngoingThis early-stage trial tests FID-007, a reformulated version of the chemotherapy drug paclitaxel, in 50 adults with advanced solid tumors that have stopped responding to standard treatments. The drug is wrapped in a special polymer to help it reach deeper into tumors while avoidi…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 17, 2026 00:45 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific genetic changes. The goal was to find the best dose and check for side effects, while seeing if the combination could shrink or s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
Experimental combo targets Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-phase study tests two oral drugs, ZEN003694 and binimetinib, together in people with advanced solid tumors that have RAS gene changes or triple-negative breast cancer. The goal is to find the safest dose and understand side effects. About 42 adults whose cancer has spr…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:44 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
New drug targets AKT mutations in Hard-to-Treat cancers
Disease control OngoingThis study tested a drug called AZD5363 in 35 people with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
New targeted drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients with advanced solid…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers had come back or stopped responding to treatment and had specific gene changes (ALK or ROS1). The goal was to see if the drug could shrink o…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug cocktail targets tough cancers with gene mutations
Disease control OngoingThis early-phase study tests a drug called neratinib combined with other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have certain gene changes (EGFR, HER2, HER3, HER4, or KRAS) and have stopped responding to standard treatments. The ma…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for kids with resistant cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had spread, returned, or stopped responding to treatment. The drug targets tumors with specific changes in FGFR genes. The main goal was to see if the drug could shrink or stop t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Targeted drug shows promise for BRCA-Linked tumors
Disease control OngoingThis study tests a drug called AZD1775 in people with advanced cancers that have a BRCA gene mutation. The drug blocks a protein that cancer cells need to grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with various solid tum…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Precision drug shows promise for rare genetic cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug blocks a faulty protein that helps cancer cells grow. The goal is to see if the drug can shrink tumors or stop the cancer from sprea…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced or hard-to…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Targeted drug duo takes on rare BRAF cancers in new trial
Disease control OngoingThis study tests two targeted drugs, dabrafenib and trametinib, in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a BRAF V600 mutation. The drugs block proteins that help cancer grow. The goal is to see if the combination can shrink tumors or stop them …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called copanlisib in 35 adults with advanced or treatment-resistant cancers that have a specific change in the PTEN gene. The drug blocks a faulty protein that helps cancer cells grow. The goal is to see if it can shrink tumors or stop them from growing fo…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug targets rare genetic flaw in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. About 49 participants will receive the drug to see if it can shrink tum…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control OngoingThis study is for people with advanced cancers that have a specific genetic change called an NF2 mutation. The drug defactinib blocks a protein that may help these cancers grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults are t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Targeted drug crizotinib tested against hard-to-treat cancers with MET gene flaw
Disease control OngoingThis study tests the drug crizotinib in people with advanced or treatment-resistant solid tumors, lymphoma, or multiple myeloma that have a specific genetic change called MET amplification. Crizotinib works by blocking signals that help cancer cells grow and spread. The main goal…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to adults with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find a dose that limits side effects while pot…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for Hard-to-Treat cancers: targeted pill shows promise
Disease control OngoingThis study tests a drug called palbociclib in people with advanced cancers that have specific genetic changes (CCND1, 2, or 3 amplification). The drug blocks certain proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from growing. About 4…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Targeted drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called taselisib in 70 people with advanced cancers (except breast cancer) that have a specific genetic change called PIK3CA mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Childhood cancer immunotherapy trial pulled before starting
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and have many genetic mutations. The goal was to see if the combination could shrink tumors or help patients l…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Targeted drug shows promise for rare cancers with cKIT mutation
Disease control OngoingThis study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. The drug works by blocking signals that make cancer cells grow. The goal is to see if the tumors shrink or stop growing. About 10 adults with various cancers (but not…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for hard-to-treat cancers with rare gene mutations
Disease control OngoingThis study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific changes in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug ca…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Targeted drug shows promise for rare genetic cancer marker
Disease control OngoingThis study tests a drug called crizotinib in 20 adults with advanced cancers that have a specific genetic change called MET exon 14 deletion. The drug works by blocking enzymes that help cancer cells grow and spread. Researchers want to see if it can shrink tumors or stop them fr…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New drug targets cancers missing PTEN gene in early trial
Disease control OngoingThis study tests a drug called GSK2636771 in people whose cancers have lost a gene called PTEN. The drug blocks a protein (PI3K-beta) that helps these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing. About 35 adults with advanced…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Targeted drug shows promise for rare Mutation-Driven cancers
Disease control OngoingThis study tested the drug trametinib in 4 people with advanced cancers that have GNAQ or GNA11 mutations. Trametinib blocks certain proteins that help these cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing.
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding a drug called methoxyamine (TRC102) to standard chemotherapy can help shrink tumors in people with advanced solid tumors or mesothelioma that have not responded to other treatments. The goal is to make cancer cells more sensitive to chemo. About 30…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Promising combo fails to shrink IDH-Mutant tumors in early trial
Disease control OngoingThis study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors that have an IDH mutation, including a type of bile duct cancer. The goal was to see if the combination could shrink or stop tumor growth. Unfortunately, no patients had their tumors s…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called binimetinib in 53 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NRAS mutation. The drug blocks proteins that help cancer grow. The main goal is to see if the drug can shrink tumors or stop…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New drug targets rare BRAF mutations in advanced cancers
Disease control OngoingThis study tests a drug called ulixertinib in 35 adults with advanced cancers that have certain BRAF gene changes (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. The main goal is to see how many patients' tumors shrink or disappear. This i…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called GSK2636771 in 24 adults with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growin…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New hope for kids with returning cancers: drug blocks tumor growth
Disease control OngoingThis study tests an experimental drug called elimusertib in children and young adults whose solid tumors have returned or not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors by blocking enzymes that cancer cells need to …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New hope for kids with hard-to-treat cancers: targeted pill attacks faulty gene pathway
Disease control OngoingThis study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New hope for Hard-to-Treat cancers: targeted pill attacks genetic weakness
Disease control OngoingThis study tests a pill called palbociclib in people with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug blocks signals that make cancer cells multiply. Researchers want to see if it can shrink tumors or stop them from growing for at least 6 months. A…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Targeted drug trial aims to block cancer growth in patients with specific genetic change
Disease control OngoingThis study is testing whether the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called a ROS1 translocation. The trial includes patients with various advanced solid tumors, lymphoma, or multiple myeloma that have not respond…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:04 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 00:46 UTC
-
Gene test trial aims to personalize cancer care for kids
Knowledge-focused OngoingThis study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 00:44 UTC
-
Scientists peek inside tumors to see how new drug fights HER2 cancers
Knowledge-focused OngoingThis early-phase study looks at how the drug DS-8201a affects tumor cells and the immune system in people with advanced HER2-positive cancers that have stopped responding to standard treatments. Researchers will take small tumor samples before and after treatment to measure chang…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC
-
Expert tumor board aims to unlock genetic secrets for advanced cancer patients
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will take part, and their doctors will either use the t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC